Sign in
Taking people in SpainPhase 4

Daridorexant for Sleep Problems in People With Major Depression

Tests daridorexant for insomnia in adults with major depressive disorder.

Key facts

Who runs it
Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
Where
Badalona, L'hospitalet De Llobregat, and Sabadell, SpainSee the 3 sites
Registry title
Study evaluating the efficacy and safety of daridorexant in patients with major depressive disorder and insomnia.
Status
Recruiting
Phase
Phase 4
People taking part
134 people, planned
Started
5 Oct 2026
Expected to end
15 Jan 2028
Type of study
Interventional
Record updated
4 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a current major depressive episode and insomnia. It tests daridorexant for sleep problems over 3 months.

Age
18-99 years old
Sex
All sexes can join.
Disease stage
A current major depressive episode in a stable phase, at least moderately severe (MADRS score of 20 or more), plus insomnia disorder confirmed by DSM-5. Stable means at least 4 weeks without significant antidepressant changes and no psychiatric hospital stay in the previous 8 weeks.
Earlier treatment
No sleep medicines (such as melatonin or benzodiazepines) for at least 30 days before the start. Sedative antidepressants or antipsychotics used for insomnia are not allowed unless the protocol allows them.

Main reasons for not taking part

  • Any other current psychiatric disorder, such as psychosis, mania or schizophrenia
  • Moderate or severe liver problems
  • Use of moderate or strong CYP3A4 inhibitor drugs
  • Sleep apnea or periodic limb movements, restless legs syndrome, narcolepsy and similar sleep disorders
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Age Range: 18-99 years old
  • Patients with a current major depressive episode according to DSM-5, in a stable phase (defined as at least 4 weeks without significant changes in antidepressant treatment and no psychiatric hospitalizations in the previous 8 weeks) and with moderate or greater severity, as indicated by a total score of ≥ 20 on the Montgomery–Åsberg Depression Rating Scale (MADRS)
  • Insomnia disorder confirmed according to DSM-5
  • Informed Consent: Ability and willingness to provide written informed consent
  • Acceptance of Protocol Requirements: Agreement to adhere to all scheduled visits, treatment plans, and study procedures

Who cannot take part

  • Concomitant Use with Moderate and potent CYP3A4 Inhibitors: Prohibited due to potential drug interaction (refer to protocol section 4.5 for specifics)
  • Use of Non-Permitted Sleep Medications: Concurrent use of melatonin, benzodiazepines, sedative antidepressants or sedative antipsychotics use for insomnia not allowed by the protocol and unwillingness to follow the slow-taper schedule constitutes an exclusion criterion
  • No concurrent sleep medications at least 30 days prior to baseline. Exclusion criteria if the patient has withdrawal symptoms and/or sleep disturbances measured by BWSQ prior to baseline
  • Other Current Psychiatric Disorders: Any current psychiatric disorder other than major depressive disorder (e.g., active psychotic disorders, mania, hypomania, acute schizophrenia, schizoaffective disorder)
  • Moderate and severe hepatic Impairment: Any hepatic condition deemed unsafe for daridorexant use
  • Substance Use Disorder: History of substance use disorder without sustained remission. Exception: past sedative abuse may be permissible if remission criteria are clearly met, as determined by the investigator
  • Uncontrolled Severe Medical Conditions: Any condition that could interfere with study procedures, safety, or outcome measures (e.g., unstable cardiovascular, respiratory, neurological, or endocrine disorders)
  • Hypersensitivity: Known allergy or hypersensitivity to daridorexant or any of its excipients
  • Specific Sleep Disorders: Sleep apnea or hypopnea index ≥ 15 events/hour (based on American Academy of Sleep Medicine criteria) or any event associated with oxygen saturation < 80% (as measured by polysomnography)
  • Periodic limb movement index ≥ 15 events/hour (as measured by polysomnography). Restless legs syndrome, circadian rhythm sleep-wake disorders, REM behavior disorder, or narcolepsy
  • Relapse or Worsening of the Main Diagnosis: Relapse of depression whose severity precludes continued participation according to the investigator’s judgment
  • Excessive Caffeine Intake: Daily consumption of >400 mg of caffeine (e.g., >4 standard cups of coffee)
  • High-Risk Alcohol Consumption: Alcohol intake above recommended risk thresholds (i.e., >4 standard drinks/day for men, >2 standard drinks/day for women)
  • Pregnancy or breastfeeding
  • Cognitive Impairments: Significant impairments that prevent the comprehension or completion of study questionnaires or procedures

Where in Spain

  • Hospital Germans Trias i PujolBadalona, SpainTaking people
  • Bellvitge University HospitalL'hospitalet De Llobregat, SpainTaking people
  • Parc Tauli Hospital UniversitariSabadell, SpainTaking people

About the trial

What the trial wants to find out

To evaluate the efficacy of Daridorexant in improving insomnia assessed with the ISI in MDD patients at 3 months.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Efficacy and Safety of Daridorexant in Patients with Major Depressive Disorder (MDD) and Insomnia: Double-blind, randomized, controlled trial
Plain-language title
Daridorexant for Sleep Problems in People With Major DepressionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
4 May 2026